5347-19-3 Usage
Description
METHYL 7-CHLORO-4-HYDROXYQUINOLINE-2-CARBOXYLATE is an organic chemical compound with a molecular formula C13H9ClN2O4. It is a derivative of quinoline and contains a chloro and a hydroxy group on the 7th and 4th carbon atoms, respectively. The presence of a methyl and a carboxylate group further enhances its reactivity and solubility. This versatile compound has potential applications in various industries, including drug discovery and development, as well as in the manufacturing of agricultural products.
Uses
Used in Pharmaceutical Industry:
METHYL 7-CHLORO-4-HYDROXYQUINOLINE-2-CARBOXYLATE is used as an intermediate in the synthesis of pharmaceuticals for its reactivity and solubility properties, contributing to the development of new drugs.
Used in Agrochemical Industry:
METHYL 7-CHLORO-4-HYDROXYQUINOLINE-2-CARBOXYLATE is used as an intermediate in the synthesis of agrochemicals, playing a role in the production of various agricultural products to improve crop protection and yield.
Check Digit Verification of cas no
The CAS Registry Mumber 5347-19-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,3,4 and 7 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 5347-19:
(6*5)+(5*3)+(4*4)+(3*7)+(2*1)+(1*9)=93
93 % 10 = 3
So 5347-19-3 is a valid CAS Registry Number.
InChI:InChI=1/C11H8ClNO3/c1-16-11(15)9-5-10(14)7-3-2-6(12)4-8(7)13-9/h2-5H,1H3,(H,13,14)
5347-19-3Relevant articles and documents
-
Breslow et al.
, p. 1232,1236 (1946)
-
SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS
-
Page 128-131, (2010/02/06)
The present invention relates to CCR5 receptor antagonists of formulae (1a) or (1b), enantiomers, diastereomers, salts and solvates thereof wherein R1, R2, R3, R4, R5, and R7 are as defined herein. The invention further includes a method of CCR5-mediated
Platelet adenosine diphosphate receptor antagonists
-
, (2008/06/13)
Compounds of the following formula (I): where a, b, R1, R2, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, met
